Neurosearch A/S Announces New Findings From the MermaiHD Phase III Study Supporting Potential Disease Modifying Properties of Huntexil(R)

Published: Mar 08, 2010

COPENHAGEN and BALLERUP, Denmark, March 8, 2010 (GLOBE NEWSWIRE) -- NeuroSearch (NEUR) today announced that further analysis of the data from the MermaiHD study with Huntexil(R) (pridopidine) for the treatment of Huntington's disease supports potential disease modifying properties of the drug.

Back to news